Lineage Cell Therapeutics, Inc.LCTXNYSE
Loading
R&D Expenses Over TimeStable
Percentile Rank36
3Y CAGR+8.2%
5Y CAGR+7.6%
Studio
Year-over-Year Change

Research and development spending

3Y CAGR
+8.2%/yr
vs -9.6%/yr prior
5Y CAGR
+7.6%/yr
Consistent
Acceleration
+17.8pp
Accelerating
Percentile
P36
Within normal range
vs 5Y Ago
1.4x
Solid growth
Streak
1 yr
Consecutive growthStable
PeriodValueYoY Change
2025$17.73M+42.2%
2024$12.47M-20.6%
2023$15.71M+12.3%
2022$13.99M-58.8%
2021$33.91M+175.3%
2020$12.32M-31.4%
2019$17.95M-14.3%
2018$20.95M-12.8%
2017$24.02M-33.5%
2016$36.11M-